175 results
8-K
EX-99.1
BCRX
Biocryst Pharmaceuticals Inc.
3 Nov 23
Regulation FD Disclosure
12:16pm
EXHIBIT 99.1
BioCryst R&D Day Highlights New Diversified Pipeline of First-in-Class/Best-in-Class Therapies with Five Programs Expected in Clinical … (R&D) Day today at 1:00p ET at the company’s Discovery Center of Excellence in Birmingham, Alabama. A live webcast of the event will be available
CORRESP
BCRX
Biocryst Pharmaceuticals Inc.
5 Feb 07
Correspondence with SEC
12:00am
Major components of R&D expenses consist of personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory … ,Accounting for Research and Development Costs. These costs are a significant component of R&D expenses. Most of our manufacturing and our clinical
8-K
EX-99.1
BCRX
Biocryst Pharmaceuticals Inc.
3 Aug 23
BioCryst Reports Second Quarter 2023 Financial Results and Provides Business Update
7:04am
, clinical trial in patients expected to begin enrollment by end of year—
—Company to host R&D day on Friday, November 3rd to introduce additional pipeline … continue to grow, we are also excited to host an R&D day in November to introduce new molecules and programs from our discovery platform that have
8-K
EX-99.1
BCRX
Biocryst Pharmaceuticals Inc.
30 Jul 09
Biocryst Reports Second Quarter 2009 Financial Results and Provides Corporate Update
12:00am
revenue from our collaboration arrangements.
Research and development (R&D) expenses decreased to $11.2 million for the second quarter of 2009 from … $13.4 million for the second quarter of 2008. The lower R&D expenses resulted from a reduction in clinical development costs associated with the peramivir
8-K
EX-99.1
BCRX
Biocryst Pharmaceuticals Inc.
6 Feb 09
Biocryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update
12:00am
recognized a $7.0 million milestone payment received from Shionogi & Co., Ltd. (Shionogi).
Research and development (R&D) expenses were $22.1 million … for the three months ended December 31, 2008, compared to $29.1 million for the three months ended December 31, 2007. The decrease in R&D expenses
8-K
EX-99.1
dzpscwvo
26 Feb 24
BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones
7:05am
8-K
EX-99.1
gzdp1j0f ed
9 Aug 06
Biocryst Reports Second Quarter 2006 Financial Results
12:00am
8-K
EX-99.1
pvukcoeb
26 Feb 14
Biocryst Reports Fourth Quarter and Full Year 2013 Financial Results
12:00am
8-K
EX-99.1
mjqyc6j2s2 ty2
8 Jan 24
Results of Operations and Financial Condition
7:02am
8-K
EX-99.1
l7aofe
3 Nov 23
Regulation FD Disclosure
12:14pm
8-K
EX-99.1
c2tlu7ll ik1izvwa8
2 Nov 23
BioCryst Reports Third Quarter 2023 Financial Results and Provides Business Update
7:05am
8-K
EX-99.1
myfm6n8s4lk 0esqz6jx
4 Mar 08
Biocryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
12:00am
8-K
EX-99.1
eg94vu2x9z7qmd1a73rk
31 Oct 08
BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update
12:00am
8-K
EX-99.1
0c55v h26yqov6xr
3 May 11
Biocryst Pharmaceuticals Announces Changes to Its Board of Directors
12:00am
8-K
EX-99.1
reau1w4thbp
29 Oct 09
Biocryst Reports Third Quarter 2009 Financial Results and Provides Corporate Update
12:00am
8-K
EX-99.1
pyr jyiz6ach2
5 Aug 10
Biocryst Reports Second Quarter 2010 Financial Results and Provides Corporate Update
12:00am
8-K
EX-99.1
qebxsbbo
15 Dec 22
BioCryst Discontinues Development of BCX9930 and Shifts Focus to Potential Once-daily, Oral Factor D Inhibitor, BCX10013
7:03am
8-K
EX-99.1
izvmpd 6uhcr
6 May 24
BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update
7:03am
8-K
EX-99.1
85846h9zg 78het
8 Nov 07
Biocryst Reports Third Quarter 2007 Financial Results and Corporate Update
12:00am